Fig. 1From: Current status of stem cell therapy for type 1 diabetes: a critique and a prospective considerationA suggested model for subcutaneous transplantation of MSC-derived IPCs. Cells are transplanted within a biological matrix. A small scaffold is cotransplanted for drug delivery. Oxygen for the immediate requirements, VEGF to induce early vascularization, nicotinamide to preserve islet viability, and exendin to promote further differentiation in vivoBack to article page